Indian companies among emerging world's vaccine heroes: Bill Gates

Billionaire philanthropist Bill Gates has showered rich praise on companies from emerging nations, including India, for donning the role of 'hidden vaccine heroes' and driving down their cost to about USD 1 per dose in the global fight to protect kids



The founder of Microsoft and co-chair of the Bill & Melinda Gates Foundation, who is to attend the World Economic Forum's Annual Meeting, said there is reason to be optimistic than ever about the future progress using vaccines to give all children a healthy start to life.

"You have probably never heard of many of the pharmaceutical companies - Serum Institute of India, Bharat Biotech, Biological E, China National Biotech Group, and Bio-Manguinhos, to name just a few - that have become some of our most valuable partners in global health," Gates said in WEF blog.

"By harnessing the same innovative spirit that transformed emerging markets into manufacturing hubs for everything... these companies have become leaders in supplying the world with high quality, low-cost vaccines," he said.


The increased competition and new manufacturing approaches created by these firms have made it possible to protect a child against eight major diseases. These include tetanus, polio and tuberculosis.

According to Gates, Serum Institute produces a higher volume of vaccines than any other company in the world and has played a key role in cutting costs and boosting volumes.

"When the GAVI Alliance first introduced it in 2001, there was one supplier and the cost was USD 3.50 per dose. As demand for the vaccine grew, GAVI encouraged other suppliers to enter the market, and the price tumbled. Now there are five suppliers, and Biological E, an Indian pharmaceutical company, announced earlier this year that it would offer the vaccine for just USD 1.19 per dose," he said.



Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email